Posts filtered by tags: Biogen[x]


 

The 20 fastest-growing, highest-paying biotechs

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:We rounded up the 20 fastest growing drugmakers that pay the most;The recently approved Alzheimer's treatment could change the way we pay for drugs;5 questions facing GlaxoSmithKline ahead of a big investor meeting.If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydiaramsey125. Let's get to it... FILE PHOTO: A technician works...
Tags: Texas, Obama, US, Trends, Compensation, Healthcare, Delta, Medicare, Fda, GlaxoSmithKline, Biotech, Humana, GSK, William Burke, Biogen, Newsletters


Dow Jones Today, Futures Tumble As Oil Stocks Dive; Adobe Leaps On Earnings; Biogen Upgraded

Access to this page has been denied because we believe you are using automation tools to browse the website.
Tags: Biogen


Biogen's debated Alzheimer's drug given to first patient

A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on...
Tags: Rhode Island, Biogen


Patient receives first infusion of Biogen's controversial Alzheimer's drug

A 70-year-old man from Rhode Island on Wednesday was the first to receive an infusion outside of a clinical trial of Biogen's...
Tags: Rhode Island, Biogen


Biogen's new Alzheimer's drug comes with "serious cost concerns" for millions on Medicare

At $56,000 per year, Aduhelm "could be a real budget-buster" for the government health program, some experts say.
Tags: Biogen


Fred DeLuca ran Subway like a titan, sleeping with franchisees' wives, micromanaging, and penny-pinching. Insiders say he set it up for failure.

Hello!Welcome to this weekly roundup of stories from Insider's Business co-Editor in Chief Matt Turner. Subscribe here to get this newsletter in your inbox every Sunday.What we're going over today:Subway cofounder Fred DeLuca ruled the company like a demigod and pursued wives of franchisees. Here's how one man sent the world's biggest fast-food chain into a tailspin.Top VCs share 46 of the most promising startups of 2021.The first new Alzheimer's drug in decades has raised co...
Tags: California, Amc, US, America, Newsletter, Trends, Nike, Amazon Prime, Hillary Clinton, Pegasus, Miami, Fidelity, Silicon Valley, Goldman Sachs, Fda, Cia


Third Member of US FDA Advisory Panel Resigns Over Alzheimer's Drug Approval

A third member of a panel of outside advisers to the U.S. Food and Drug Administration has resigned in protest over the agency's decision to approve Biogen's Alzheimer's disease treatment despite the committee's recommendation against doing so. Reuters reports: Aaron Kesselheim, a Professor of Medicine at Harvard Medical School who had served on the FDA's advisory committee for nervous system drugs since 2015, told Reuters on Thursday he was stepping down from the panel. "My rationale was that t...
Tags: US, Tech, Fda, Reuters, U S Food and Drug Administration, Harvard Medical School, Washington University, Biogen, Aaron Kesselheim, Kesselheim, FDA Advisory Panel, David Knopman, Joel Perlmutter, Aduhelm Mayo Clinic


What a controversial drug approval could mean for future Alzheimer's treatments

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and this week in healthcare news:A controversial Alzheimer's drug approval poses some big challenges for the future of the field;We chronicled the history of Noom, which raised $540 million from top investors after spending a decade trying to crack the weight-loss app business;Amazon and Walmart face off on discounting prescriptions.If you're new to this newsletter, sign up here. Tips, comments? Email me at [email protected]
Tags: Amazon, Newsletter, Trends, Walmart, Alzheimer's Disease, Healthcare, Food And Drug Administration, Fda, Morgan Stanley, Silver Lake, Pharmacy, Shelby, Megan, Allison, Gabby, Biogen


Top Stories this AM: A tentative infrastructure deal is struck; a COVID outbreak at a maskless crypto conference; elf ears are in

Good morning and welcome to your weekday morning roundup of the top stories you need to know.For more daily and weekly briefings, sign up for our newsletters here.What's going on today: Infrastructure - we've got it? Bipartisan Senate group strike early $1.2 trillion infrastructure agreement as Democrats grow impatient. The tentative deal faces a steep climb in both parties. Democrats want tax hikes, while Republicans are likely to balk at fresh spending. Ears the thing. People in China ...
Tags: News, China, US, Newsletter, Trends, Miami, Fda, Biden, Miller, Trump, Biogen, Jason Miller, Aaron Kesselheim, Bipartisan Senate, Longtime Trump, Top Stories This Am


A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug

Atthapon Raksthaput/Shutterstock A third member of an FDA expert panel has resigned over the agency's accelerated approval of a new Alzheimer's drug. The committee voted against approving the treatment. The FDA isn't required to follow the panel's recommendation but usually does. Aduhelm failed one of its late-stage clinical trials and didn't produce conclusive results in another trial. See more stories on Insider's business page. A third member of a Food and Drug...
Tags: Science, News, US, Trends, Healthcare, Food And Drug Administration, Alzheimer's, Fda, Mayo Clinic, Cnbc, Harvard Medical School, Biogen, Washington University in St Louis, Aaron Kesselheim, Knopman, Kesselheim


Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug

A third member of a key FDA panel has resigned over the agency's controversial decision to approve Biogen's new Alzheimer's drug,...
Tags: Fda, Biogen


Biogen's new Alzheimer's drug could cost Medicare billions of dollars a year, report finds

Biogen's new Alzheimer's drug, Aduhelm, could cost Medicare billions of dollars a year, according to an analysis by the nonprofit Kaiser...
Tags: Biogen


2 FDA committee members resign over Biogen Alzheimer's drug approval

Fallout over the FDA’s recent decision to grant Biogen’s Alzheimer’s drug accelerated approval has seen two advisory panel members resign.
Tags: Fda, Biogen, Biogen Alzheimer


A “disgraceful decision:” Researchers blast FDA for approving Alzheimer’s drug (ars technica)

Enlarge (credit: Getty | Congressional Quarterly) The US Food and Drug Administration on Monday approved the antibody drug Aduhelm (generic name aducanumab) to treat Alzheimer’s disease. Aduhelm is the first new Alzheimer’s drug to earn FDA approval since 2003. It’s also the first drug to target a theoretical cause of the irreversible neurodegenerative disease—clumps of beta-amyloid peptides that build up in the brains of Alzheimer's patients—rather than just treating the disease’s symptoms. T...
Tags: News, US, Fda, Beth Mole, US Food and Drug Administration, Biogen, Aduhelm


“Alzheimer’s is open for business:” Controversial FDA approval could pave the way for future drugs

On Monday, a 17-year drought in the world of Alzheimer’s drugs ended with the FDA approval of Biogen’s Aduhlem (aducanumab). The controversy behind the FDA’s decision was considerable, but it doesn’t seem to be spooking drug developers who are now narrowing in on the degenerative brain disease.  In a nutshell, the approval of Aduhelm came after conflicting results from clinical trials. In November 2020 an independent FDA advisory board did not recommend that the agency endorse the drug, b...
Tags: Health, TC, Tech, Medicare, SEC, Dementia, Fda, Life Sciences, Ward, Biogen, Eli Lilly, Drug Development, Drug Discovery, Therapeutics, Esai, Alzheimer 's Association


The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:We found the 9 biotechs that stand to benefit after the FDA approved a new Alzheimer's drug;A top investor at General Atlantic explained why he's betting on telemedicine;Clover Health got the WallStreetBets treatment, closing up more than 80% on Tuesday.If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected] or tweet @lydiaramsey125. Let's get t...
Tags: Mexico, Trends, Bloomberg, Canada, Atlantic, Healthcare, Alzheimer's, Fda, Biotech, General Atlantic, Gamestop, Clover Health, Chamath Palihapitiya, Robb, US State Department, Biogen


US stocks gain to near-record levels as yields fall to 1-month low

Spencer Platt/Getty Images US stocks gained to near-record levels on Tuesday as inflation concerns eased due to falling yields and commodity prices.The tech-heavy Nasdaq 100 led the rally higher for the second day in a row, jumping almost half a percent.Copper and lumber prices are down about 8% and 30% from their recent high, respectively.Sign up here for our daily newsletter, 10 Things Before the Opening Bell.The tech-heavy Nasdaq 100 led the stock market higher on Tuesday, extending its...
Tags: Congress, China, US, Trends, Markets, Tesla, Reddit, Berkshire Hathaway, Warren Buffett, Fda, US Treasury, Stock Market, Dow Jones, Irs, S&P 500, Dow Jones Industrial Average


Biogen, FDA at odds over timing of confirmatory trial of Alzheimer's drug

The FDA considers a nine-year timeline to be a “conservative estimate” and a “starting point” for talks with Biogen, an official said.
Tags: Fda, Biogen, Biogen FDA


FDA Approval of New Alzheimer’s Drug May Boost Prospects of Other Treatments

The FDA’s reasoning for greenlighting Biogen’s Aduhelm could bode well for other Alzheimer’s drugs targeting the disease in a similar way.
Tags: Fda, Biogen


The FDA approved a drug to treat the underlying cause of Alzheimer's and potentially slow its progression. But not all doctors are willing to prescribe it.

The FDA approved the first drug to treat the underlying cause of Alzheimer's. Morsa Images/Getty Images Hello! This story is from today's edition of Morning Brew, an awesome daily email read by 2.9 million next-generation leaders like you. Sign up here to get it!Yesterday, the FDA approved Biogen's aducanumab, the first drug to treat the underlying cause of Alzheimer's (sticky brain plaques) and potentially slow the disease's progression in early stage patients. Altho...
Tags: US, Trends, Fda, Reuters, Biogen, Alex Hickey


Biogen faces tough questions over $56K-a-year price of newly approved Alzheimer's drug

Biogen on Tuesday faced tough questions from Wall Street analysts over the $56,000 annual cost of its newly approved Alzheimer's drug, Aduhelm.
Tags: Biogen


Biogen gets FDA approval for Alzheimer's treatment

Julie Hyman and Anjalee Khemlani breakdown what the FDA’s approval of Biogen’s Alzheimer’s drug will mean for the pharmaceutical...
Tags: Fda, Biogen, Julie Hyman, Anjalee Khemlani


Biotech Stocks: Big Winners After Biogen's Aduhelm Approval

Insider identified 9 healthcare companies that the market and Wall Street analysts see as benefiting from approval of Aduhelm.
Tags: Biogen


We just got the first new Alzheimer's drug in nearly 2 decades

Hello,Welcome to Insider Healthcare. I'm Lydia Ramsey Pflanzer, and today in healthcare news:On Monday, the FDA approved the first new Alzheimer's drug in nearly two decades;Primary care company One Medical wants to tap into senior care by acquiring competitor Iora Health;We looked into an old Medicare policy that could get in the way of patients accessing the newly approved Alzheimer's drug.If you're new to this newsletter, sign up here. Comments, tips? Email me at [email protected]
Tags: Washington Post, US, Trends, Getty Images, Alzheimer's Disease, Healthcare, Medicare, Fda, Biotech, Biden, Fairfax Media, William Burke, Biogen, Newsletters, Primary Care, One Medical


US stocks gain as drop in commodity prices help ease inflation concerns

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 5, 2020. Andrew Kelly/Reuters US stocks gained on Tuesday as inflation concerns eased due to falling commodity prices.The tech-heavy Nasdaq 100 led the rally higher for the second day in a row, jumping half a percent.WTI Crude Oil fell about 2% from its recent high of $70 per barrel, while copper prices are down about 8% from its recent high.Sign up here for our daily newsletter, 10 Things Before t...
Tags: China, New York City, US, Trends, Markets, Tesla, Reddit, Trading, Berkshire Hathaway, Warren Buffett, Fda, Stock Market, Dow Jones, S&P 500, Dow Jones Industrial Average, Chamath Palihapitiya


Warren Buffett's Berkshire Hathaway scores $60 million gain on Biogen after FDA approval sends the stock to record high

Warren Buffett Bill Pugliano/Getty Warren Buffett's Berkshire Hathaway made a $60 million gain on Biogen shares on Monday. The biotech stock closed 38% higher after regulators approved its Alzheimer's drug. Berkshire's stake has jumped in value by $75 million in the past 18 months. See more stories on Insider's business page. Warren Buffett's Berkshire Hathaway scored a $60 million gain on Biogen shares after they surged to a record high on Monday. Federal regulators ap...
Tags: Trends, American Express, Berkshire Hathaway, Warren Buffett, Fda, Pfizer, Berkshire, Buffett, US Food and Drug Administration FDA, Biogen, Coca Cola However, Theron Mohamed, Warren Buffett Bill Pugliano Getty Warren Buffett, Notably Berkshire, AbbVie Merck Bristol Myers Squibb


Cowen upgrades Biogen and doubles price target after Alzheimer's drug approval

The company's stock surged 38% on Monday following the approval of the drug, which goes by the name Aduhelm.
Tags: Biogen, Cowen


FDA approval of Biogen's Alzheimer's drug leaves some 'disappointed'

Government health officials on Monday approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from...
Tags: Fda, Biogen


Global stocks hover below record highs ahead of US inflation data, while oil falls for a 2nd day as demand optimism fades

Spencer Platt/Getty Images Global stocks traded just under record highs as investors awaited inflation data later this week. Bitcoin fell to two-week lows around $33,000, while other major tokens fell more than 9%. Oil retreated from 2-year highs, but slowing cases of COVID-19 might limit losses. Sign up here for our daily newsletter, 10 Things Before the Opening Bell. Global stocks mostly edged lower on Tuesday as investors remained focused on inflation data, with the US consumer price i...
Tags: Europe, UK, London, India, US, Trends, Joe Biden, Frankfurt, Bitcoin, Shanghai, Ubs, Deutsche Bank, Cornwall, Tokyo, Brent, Fda


Alzheimer's Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

Despite scant evidence that it works, the drug, Aduhelm, is predicted to generate billions of dollars in revenue, much of it from Medicare.
Tags: Biogen